Valsartan

• CAT Number: A000712
• CAS Number: 137862-53-4
• Molecular Formula: C₂₄H₂₉N₅O₃
• Molecular Weight: 435.52
• Purity: ≥95%
• Synonyms: 137862-53-4; Diovan; Provas; Tareg; L-Valsartan
• Target: Angiotensin Receptor
• Solubility: >19.7mg/mL in DMSO
• Storage: -20°C
• InChI: InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
• InChIKey: ACWBQPMHZXGDFX-QFIPXVFZSA-N
• SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O

Valsartan is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor. Valsartan is mainly used for treatment of high blood pressure, congestive heart failure, and to increase the chances of living longer after a heart attack. Valsartan is used to treat high blood pressure, congestive heart failure, and to reduce death for people with left ventricular dysfunction after having had a heart attack.

Reference

1: Del Val A, García Campos M, García Morales N. Sprue-like enterophaty
asscociated with valsartan. Med Clin (Barc). 2017 Nov 14. pii:
S0025-7753(17)30783-2. doi: 10.1016/j.medcli.2017.09.021. [Epub ahead of print]
English, Spanish. PubMed PMID: 29150128.

2: Institute for Quality and Efficiency in Health Care. Sacubitril / Valsartan —
Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne,
Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2016 Mar
30. Available from http://www.ncbi.nlm.nih.gov/books/NBK458434/
PubMed PMID: 29144684.

3: Ashy N, Nguyen TN, Denhaerynck K, Gharaibeh M, Alhossan A, Vancayzeele S, Brié
H, Aerts A, MacDonald K, Abraham I. Hierarchical Modeling of Patient and
Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with
and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with
15,282 Evaluable Patients. Int J Chronic Dis. 2017;2017:9842450. doi:
10.1155/2017/9842450. Epub 2017 Sep 25. PubMed PMID: 29142906; PubMed Central
PMCID: PMC5632928.

4: Karim MA, Siddiqui HU, Ullah S, Khan NAJ. Sacubitril/Valsartan: Practice
Changing Guideline in the Management of Congestive Heart Failure. J Coll
Physicians Surg Pak. 2017 Nov;27(11):733. doi: 2756. PubMed PMID: 29132491.

5: Shaddy R, Canter C, Halnon N, Kochilas L, Rossano J, Bonnet D, Bush C, Zhao Z,
Kantor P, Burch M, Chen F. Design for the sacubitril/valsartan (LCZ696) compared
with enalapril study of pediatric patients with heart failure due to systemic
left ventricle systolic dysfunction (PANORAMA-HF study). Am Heart J. 2017
Nov;193:23-34. doi: 10.1016/j.ahj.2017.07.006. Epub 2017 Jul 17. PubMed PMID:
29129252.

6: Chen L, Yan KP, Liu XC, Wang W, Li C, Li M, Qiu CG. Valsartan regulates
TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve
doxorubicin-induced heart failure. Arch Pharm Res. 2017 Nov 9. doi:
10.1007/s12272-017-0980-4. [Epub ahead of print] PubMed PMID: 29124661.

7: Fujiwara T, Hoshide S, Yano Y, Kanegae H, Kario K. Comparison of morning vs
bedtime administration of the combination of valsartan/amlodipine on nocturnal
brachial and central blood pressure in patients with hypertension. J Clin
Hypertens (Greenwich). 2017 Nov 5. doi: 10.1111/jch.13128. [Epub ahead of print]
PubMed PMID: 29106031.

8: Ishak J, Rael M, Punzi H, Gradman A, Anderson LM, Patel M, Ali S, Ferguson W,
Neutel J. Additivity of nebivolol/valsartan single-pill combinations versus other
single-pill combinations for hypertension. J Clin Hypertens (Greenwich). 2017 Nov
5. doi: 10.1111/jch.13132. [Epub ahead of print] PubMed PMID: 29105958.

9: Metra M. What will be the impact of sacubitril/valsartan in clinical practice?
J Cardiovasc Med (Hagerstown). 2017 Oct 27. doi: 10.2459/JCM.0000000000000568.
[Epub ahead of print] PubMed PMID: 29084021.

10: Abadir P, Hosseini S, Faghih M, Ansari A, Lay F, Smith B, Beselman A, Vuong
D, Berger A, Tian J, Rini D, Keenahan K, Budman J, Inagami T, Fedarko N, Marti G,
Harmon J, Walston J. Topical Reformulation of Valsartan for Treatment of Chronic
Diabetic Wounds. J Invest Dermatol. 2017 Oct 24. pii: S0022-202X(17)33036-1. doi:
10.1016/j.jid.2017.09.030. [Epub ahead of print] PubMed PMID: 29078982.